Welcome to the October edition of the Edison Healthcare Insight. In this edition we have profiled 34 of our healthcare companies under coverage.
Readers wishing more detail should visit our website, where reports are freely available for download (www.edisongroup.com). All profit and earnings figures shown are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multisector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
We welcome any comments/suggestions our readers may have.
Download October 2022 edition of Edison Healthcare Insight here
Incannex (NYSE:IXHL, ASX:IHL) is an Australian biotech company specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies.
Get access to the very latest content matched to your personal investment style.